kyron.bio
Glycan engineering for therapeutic proteins.
kyron.bio uses precision glycan engineering to enhance antibody and protein therapeutics. Their platform controls glycosylation patterns to improve efficacy, safety, and manufacturability—delivering advanced biologics with better patient outcomes.
Founders
Emilia McLaughlin
Cofounder
Emilia holds a PhD in Cell and Molecular Biology from Institut Pasteur and brings over six years of experience researching evolutionarily diverse life forms. She has been awarded multiple research grants and has co-authored five scientific publications, including two as first author.